Ironwood price target lowered to $14 from $20 at Wells Fargo

Wells Fargo lowered the firm’s price target on Ironwood to $14 from $20 and keeps an Overweight rating on the shares. The firm thinks Ironwood has a drug on hand and differentiation could come from the sales effort and weekly dosing, but the lack of other clinical differentiation brings down peak sales to $500M, the analyst tells investors in a research note.